Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från BioStock via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
2025-12-11 10:45:00
As OncoZenge prepares for its European phase III pain management programme for BupiZenge – with first patient targeted for Q2026 XNUMX – the company is advancing key clinical, manufacturing and operational workstreams. OncoZenge recently appointed co-inventor Dr. Torben Mogensen to its advisory board, and BioStock reached out to him for a comment.
Read the full interview at biostock.se:
The inventor behind BupiZenge takes a seat on OncoZenge's advisory board ahead of phase III
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/